Palisade Bio

GI-focused biotech

PALI · Nasdaq · United States

Share price · PALI

$0.94-1.10 (-53.82%) 3M

close as of 2026-11-18 · 24h delayed · vol 5.5M (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PALI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Sep 2026-16.1%

    Nothing announced by PALI that day or the session before.

  2. 13 Aug 2026+9.7%

    Nothing announced by PALI that day or the session before.

  3. 12 Aug 2026-8.4%

    Nothing announced by PALI that day or the session before.

  4. 29 Jun 2026+18.0%
  5. 22 Apr 2026-16.4%
  6. 21 Apr 2026+12.0%
  7. 15 Apr 2026+13.6%

    Nothing announced by PALI that day or the session before.

  8. 30 Mar 2026-11.0%
  9. 5 Jan 2026-16.0%

    Nothing announced by PALI that day or the session before.

Share of unusual movement by asset

For each asset, the share of PALI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
PALI-2108
events and moves
82%
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—95%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
PDE4Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
PALI-2108Phase 2Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Est. primary completion 2027-10 · NCT07845487 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 March 2026Topline resultPALI-2108Phase 1b of PALI-2108 in fibrostenotic Crohn's disease: topline results
Palisade Bio · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$11M$114M$15M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.5M$7.4M$125M$11M-$7.6M operating cash flowreport ↗
2026-Q1—$6.4M$133M$3.9Mreport ↗
2025-Q3—$1.4M$5.2M$2.9M-$3.5M operating cash flowreport ↗
2025-Q2—$1.7M$5.4M$2.8M-$1.8M operating cash flowreport ↗
2025-Q1—$0.9M$7.2M$2.2M-$2.3M operating cash flowreport ↗
2024-Q3$0$2.1M$8.0M$3.5M-$3.1M operating cash flowreport ↗
2024-Q2$0$2.6M$11M$4.1M-$3.5M operating cash flowreport ↗
2024-Q1$0$2.2M$11M$3.5M-$3.2M operating cash flowreport ↗
2023-Q3$0$1.7M$15M$3.6M-$2.7M operating cash flowreport ↗
2023-Q2$0$2.2M$16M$3.4M-$2.2M operating cash flowreport ↗
2023-Q1$0.3M$1.2M$13M$2.3M-$3.5M operating cash flowreport ↗
2022-Q3$0$1.9M$14M$4.0M-$3.0M operating cash flowreport ↗
2022-Q2$0$1.3M$5.0M$2.3M-$3.3M operating cash flowreport ↗
2022-Q1$0$1.0M$6.6M$4.2M-$3.8M operating cash flowreport ↗
2021-Q3—$0.6M$14M—-$2.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$10M$133M$4.2M-$11M operating cash flowreport ↗

For fiscal-year 2025, Palisade Bio did not disclose revenue (prior year $0M), reported R&D spend of $10.19M, up 12.5% YoY from $9.06M, cash and equivalents of $133.39M, and a net loss of $16.78M, with quarterly net burn of $16.78M.

Palisade Bio is advancing PALI-2108, a PDE4 inhibitor prodrug for inflammatory bowel disease. During the year, it completed dosing of 89 subjects in the Phase 1 study’s SAD, MAD, food-effect, and UC cohorts and reported positive safety, tolerability, and pharmacokinetic results. The company also dosed first patients in an exploratory Phase 1b fibrostenotic Crohn’s disease cohort in October 2025 and anticipates FDA IND submissions for a Phase 2 UC study in the second quarter of 2026 and a Phase 2 Crohn’s disease study in the second half of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$9.1M$9.8M$3.6M-$12M operating cash flowreport ↗
2023-FY$0.3M$6.9M$12M$3.1M-$11M operating cash flowreport ↗
2022-FY$0$6.5M$12M$3.6M-$13M operating cash flowreport ↗
2021-FY—$2.4M$11M$6.7M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 11 purchases ($347K), 4 sales ($420K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Baltera Robert Jr. · directorOpen-market purchase50,000$1.01$50KForm 4
2026-10-19Capers Julien E. · See RemarksAward / grant787,300——Form 4
2026-10-06Finley John David · director, CEO CFOOption exercise3,227,384——Form 4
2026-10-06Jones Mitchell Lawrence · See RemarksOption exercise2,620,850——Form 4
2026-10-06Finley John David · director, CEO CFOTax withholding1,411,982$1.49$2.1MForm 4
2026-10-06Jones Mitchell Lawrence · See RemarksTax withholding1,031,102$1.49$1.5MForm 4
2026-10-06Finley John David · director, CEO CFOOption exercise (derivative)3,059,800——Form 4
2026-10-06Jones Mitchell Lawrence · See RemarksOption exercise (derivative)2,555,266——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 96 reporting institutions held 146.7M shares ($256.4M, 81.8% of shares outstanding).

#InstitutionSharesValue
1B Group, Inc.11,414,285$20.0M
2JANUS HENDERSON GROUP PLC10,689,452$18.8M
3Octagon Capital Advisors LP10,276,317$18.0M
4PERCEPTIVE ADVISORS LLC8,928,149$15.6M
5AMERIPRISE FINANCIAL INC8,711,385$15.2M
6Commodore Capital LP7,181,062$12.6M
7RA CAPITAL MANAGEMENT, L.P.7,124,116$12.5M
8FRANKLIN RESOURCES INC5,785,189$10.1M
9GOLDMAN SACHS GROUP INC5,373,951$9.4M
10Eversept Partners, LP4,987,499$8.7M
11Boxer Capital Management, LLC4,799,875$8.4M
12MORGAN STANLEY4,551,533$8.0M
13ADAGE CAPITAL PARTNERS GP, L.L.C.4,500,000$7.9M
14GREAT POINT PARTNERS LLC3,405,757$6.0M
15Balyasny Asset Management L.P.3,270,845$5.7M